Oestrogen receptor (ERα), progesterone receptor and HER2 triple-negative breast cancer (TNBC) comprises ∼15–20% of breast cancers and has the worst prognosis because of a lack of effective therapeutic targets3 and distant vital organ metastases4. This evidence concerns the gene ERBB2 and breast carcinoma.